Archives

Circadian Therapeutics and Arquimea Collaboration

Circadian Therapeutics and Arquimea Collaboration Circadian Therapeutics and ARQUIMEA sign a collaboration agreement for the development of casein kinase 1 inhibitors for the treatment of diseases affecting the nervous system Co-development of molecules as an...

New CT Research Published

New CT Research Published Adenosine integrates light and sleep signalling for the regulation of circadian timing in mice New research, published today in Nature Communications by Circadian Therapeutics founders and collaborators, identifies an adenosine-based...

Circadian Therapeutics Announce the Appointment of Dr. Mark Sampson

Circadian Therapeutics Announce the Appointment of Dr. Mark Sampson  Circadian Therapeutics Ltd is delighted to announce the appointment of Dr Mark Sampson as Chief Executive Officer and Board Member of the Company, effective 1st July 2020. Most recently Chief Medical...

Study Links Exposure to Light at Night to Depression

Study Links Exposure to Light at Night to Depression Researchers at the Nara Medical University School of Medicine in Nara, Japan, performed a two year study on 863 subjects. The study found that the link between light exposure and depression occurred even when the...
Collaboration with Blind Veterans UK

Collaboration with Blind Veterans UK

Collaboration with Blind Veterans UK The launch of our exciting research collaboration with the Blind Veterans UK Charity. Nigel Jones, Managing Director and COO of Circadian Therapeutics (CT) is pictured signing the research collaboration agreement with Major General...

Therapeutics that treat the causes, not just the symptoms

Contact

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

contact@circadiantherapeutics.com

+44 (0) 1865 546581

Registered Office

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

Registered No 10283353.

PRIVACY POLICY

© Circadian Therapeutics 2018.
All rights reserved.

Website Design by Brand Cooke

Accessibility